PT  - JOURNAL ARTICLE
AU  - OJIMA, TOSHIYASU
AU  - NAKAMORI, MIKIHITO
AU  - NAKAMURA, MASAKI
AU  - KATSUDA, MASAHIRO
AU  - HAYATA, KEIJI
AU  - KATO, TOMOYA
AU  - KITADANI, JUNYA
AU  - TABATA, HIROTAKA
AU  - TAKEUCHI, AKIHIRO
AU  - IWAHASHI, MAKOTO
AU  - YAMAUE, HIROKI
TI  - Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus
DP  - 2016 Feb 01
TA  - Anticancer Research
PG  - 829--834
VI  - 36
IP  - 2
4099  - http://ar.iiarjournals.org/content/36/2/829.short
4100  - http://ar.iiarjournals.org/content/36/2/829.full
SO  - Anticancer Res2016 Feb 01; 36
AB  - Background: The aim of this phase II study was to evaluate the feasibility of a neoadjuvant chemotherapy regimen consisting of divided-dose docetaxel and cisplatin, with 5-fluorouracil (NAC-DCF), for treatment of patients with stage II/III squamous cell carcinoma of the esophagus (SCCE). Patients and Methods: The NAC-DCF regimen, consisting of 2-h infusion of docetaxel at 35 mg/m2 on days 1 and 8, 4-h infusion of cisplatin at 12 mg/m2 on days 1-5, and continuous infusion of 5-fluorouracil at 600 mg/m2 on days 1-5, was administered. We compared NAC-DCF with conventional NAC-CF. Results: The DCF group comprised of 45 patients, and the CF group comprised of 28 patients. The incidence of grade 3/4 neutropenia was significantly higher in the DCF group (56%) than in the CF group (0%). Grade 2/3 pathological response was attained in a significantly higher percentage of patients in the DCF group (40%) than in the CF group (11%) (p=0.0153). Conclusion: This DCF regimen led to a high frequency of pathological responses among patients with advanced SCCE.